Bowman SJ, Fox R, Dorner T, Mariette X, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 2022;399:161-171.
PMID: 34861168